$2.3 Billion is the total value of Redmile Group, LLC's 70 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -1,360 | -100.0% | -0.01% | – |
| LHCG | Exit | LHC GROUP INC | $0 | – | -3,310 | -100.0% | -0.01% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -6,640 | -100.0% | -0.02% | – |
| HOLX | Exit | HOLOGIC INC | $0 | – | -20,000 | -100.0% | -0.04% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -332,310 | -100.0% | -0.10% | – |
| Exit | NEURODERM LTD | $0 | – | -76,729 | -100.0% | -0.15% | – | |
| AMED | Exit | AMEDISYS INC | $0 | – | -283,648 | -100.0% | -0.78% | – |
| MEDP | Exit | MEDPACE HLDGS INC | $0 | – | -499,640 | -100.0% | -0.79% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -603,493 | -100.0% | -0.87% | – |
| DPLO | Exit | DIPLOMAT PHARMACY INC | $0 | – | -957,155 | -100.0% | -0.98% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -723,330 | -100.0% | -1.24% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -189,008 | -100.0% | -1.42% | – |
| MOH | Exit | MOLINA HEALTHCARE INC | $0 | – | -461,074 | -100.0% | -1.56% | – |
| Exit | ARRAY BIOPHARMA INCnote 3.000% 6/0 | $0 | – | -19,000,000 | -100.0% | -1.69% | – | |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -338,536 | -100.0% | -1.70% | – |
| AET | Exit | AETNA INC NEW | $0 | – | -233,837 | -100.0% | -1.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-11 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.